These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27457311)

  • 1. Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.
    Pal S; Veeravalli SC; Das SK; Shobha V; Uppuluri RR; Dharmanand BG; Nadkar M; Hsia E; Fei K; Yao R; Khalifa A
    Int J Rheum Dis; 2016 Nov; 19(11):1083-1092. PubMed ID: 27457311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
    Combe B; Dasgupta B; Louw I; Pal S; Wollenhaupt J; Zerbini CA; Beaulieu AD; Schulze-Koops H; Durez P; Yao R; Vastesaeger N; Weng HH;
    Ann Rheum Dis; 2014 Aug; 73(8):1477-86. PubMed ID: 23740226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.
    Dasgupta B; Combe B; Louw I; Wollenhaupt J; Zerbini CA; Beaulieu A; Schulze-Koops H; Durez P; Wolff V; Yao R; Weng HH; Govoni M; Vastesaeger N
    Arthritis Care Res (Hoboken); 2014 Dec; 66(12):1799-807. PubMed ID: 24839031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population.
    Jeka S; Batko B; Korkosz M; Majdan M; Kwiatkowska B; Dankiewicz-Fares I; Sobiecki JM; Samborski W
    Adv Clin Exp Med; 2018 Apr; 27(4):493-499. PubMed ID: 29558044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain.
    Alonso A; González CM; Ballina J; García Vivar ML; Gómez-Reino JJ; Marenco JL; Fernández-Nebro A; Ordás C; Cea-Calvo L; Arteaga MJ; Sanmartí R
    Reumatol Clin; 2015; 11(3):144-50. PubMed ID: 25022442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.
    Scrivo R; Conti F; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
    Reumatismo; 2009; 61(2):107-17. PubMed ID: 19633797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
    Vastesaeger N; Kutzbach AG; Amital H; Pavelka K; Lazaro MA; Moots RJ; Wollenhaupt J; Zerbini CA; Louw I; Combe B; Beaulieu A; Schulze-Koops H; Dasgupta B; Fu B; Huyck S; Weng HH; Govoni M; Durez P
    Rheumatology (Oxford); 2016 Aug; 55(8):1466-76. PubMed ID: 27114562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study.
    Durez P; Vanthuyne M; Soyfoo MS; Hoffman I; Malaise M; Geusens P
    Acta Clin Belg; 2017 Dec; 72(6):424-428. PubMed ID: 28431485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study.
    Yonemoto Y; Okamura K; Takeuchi K; Ayabe K; Kaneko T; Matsushita M; Tamura Y; Iso T; Okura C; Otsuka K; Inoue H; Takagishi K
    Mod Rheumatol; 2016; 26(1):24-8. PubMed ID: 26140464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study.
    Psaltis D; Settas L; Georgiadis A; Koukli E; Bounas A; Livieratos A; Petrikkou E; Kalogiannaki H; Repa A; Vassilopoulos D; Sidiropoulos P
    Rheumatol Int; 2022 Apr; 42(4):639-650. PubMed ID: 35091757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
    Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
    Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.
    Durez P; Pavelka K; Lazaro MA; Garcia-Kutzbach A; Moots RJ; Amital H; Govoni M; Vastesaeger N
    Clin Rheumatol; 2018 May; 37(5):1417-1420. PubMed ID: 29611083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
    Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
    J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis.
    Wiacek R; Kolossa K; Jankowski T; Jeka S; Karmowski A; Karmowski M; Gworys B
    Adv Clin Exp Med; 2012; 21(3):337-42. PubMed ID: 23214197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.